Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity

Summary

Fondaparinux is a synthetic pentasaccharide consisting of the minimal sequence of heparin which interacts with antithrombin (AT). It represents a new class of selective factor Xa inhibitors without any antithrombin activity. It has been shown to exhibit potent antithrombotic properties in clinical studies. However, the mechanism of its antithrombotic action has not yet been fully established. In the present study it was shown that fondaparinux, used at pharmacological concentration (500 ng/ml), rendered the clot more susceptible to fibrinolysis induced by t-PA: plasma fibrin clots formed in the presence of fondaparinux and perfused with t-PA were degraded at a faster rate than those formed in the absence of fondaparinux. This fibrinolytic activity of fondaparinux is mainly due to a modification of clot structure characterized by a loose fibrin conformation with less branched fibers and the presence of large pores in comparison to control clots which present a tighter conformation. The difference in fibrin structure was responsible for an increase in clot porosity leading to a better availability of t-PA to the fibrin network. It is related to the decrease in thrombin generation, in an AT-dependent pathway. It was also demonstrated that in the presence of exogenous thrombomodulin, the inhibition of TAFI activation by fondaparinux could contribute, to a lesser extent, to the increased thrombus lysis. The increase in t-PA induced thrombus lysis could contribute to the antithrombotic activity of fondaparinux.

Keywords

Fondaparinux - clot structure - fibrinolysis - fibrin network

• References

• 1 Petitou M, Duchaussoy P, Herbert JM. et al The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
• 2 The Matisse Investigators Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 867-73.
• 3 Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005; 4: 707-21.
• 4 Yusuf S, Mehta SR, Chrolavicius S. et al Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-30.
• 5 Walenga JM, Jeske WP, Fareed J. Short-and longacting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005; 14: 847-58.
• 6 Wessler S. Yin ET. On the antithrombotic action of heparin. Thromb Diath Haemorrh 1974; 32: 71-8.
• 7 Walenga JM, Jeske WP, Bara L. et al Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide. Thromb Res 1997; 86: 1-36.
• 8 Blomback B, Carlsson K, Fatah K. et al Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
• 9 Blomback B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 1994; 75: 327-8.
• 10 Collet JP, Soria J, Mirshahi M. et al Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
• 11 Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25: 311-9.
• 12 Parise P, Morini M, Agnelli G. et al Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis 1993; 4: 721-7.
• 13 Bacher P, Welzel D, Iqbal O. et al The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res 1992; 66: 151-8.
• 14 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-62.
• 15 Lisman T, Bijsterveld NR, Adelmeijer J. et al Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of Fondaparinux. J Thromb Haemost 2003; 1: 2368-73.
• 16 Okada M, Blomback B. Factors influencing fibrin gel structure. Ann NY Acad Sci 1983; 408: 233-53.
• 17 Wang W, Nagashima M, Schneider M. et al Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-7.
• 18 Collet JP, Mishal Z, Lesty C. et al Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications:a possible mechanism for the high thrombotic tendency?. Thromb Haemost 1999; 82: 1482-9.
• 19 Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
• 20 Viles-Gonzalez JF, Gaztanaga J, Zafar UM. et al Clinical and experimental experience with factor Xa inhibitors. Am J Cardiovasc Drugs 2004; 4: 379-84.
• 21 Mohri H, Iwamatsu A, Ohkubo T. Heparin binding sites are located in a 40-kD gamma-chain and a 36-kD beta-chain fragment isolated from human fibrinogen. J Thromb Thrombolysis 1994; 1: 49-54.
• 22 Odrljin TM, Shainoff JR, Lawrence SO. et al Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996; 88: 2050-61.
• 23 Yakovlev S, Gorlatov S, Ingham K. et al Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site. Biochemistry 2003; 42: 7709-16.
• 24 Paolucci F, Clavies MC, Donat F. et al Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41: 11-8.
• 25 Herbert JM, Herault JP, Bernat A. et al Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.